Intranasal COVID-19 therapeutic shows promise in preclinical trials

The coronavirus disease 2019 (COVID-19) pandemic continues to rage in many countries over a year after it first emerged in Wuhan, China. New and more infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are emerging, with concern mounting over their natural and vaccine-induced immunity evasion potential.

Rapid development and deployment of non-invasive therapeutic measures to prevent infection by all SARS-CoV-2 variants could complement the currently ongoing vaccination efforts. It will also help put an end to this unprecedented COVID-19 pandemic.

Study: An intranasal ASO therapeutic targeting SARS-CoV-2. Image Credit: strannik65 / Shutterstock
Study: An intranasal ASO therapeutic targeting SARS-CoV-2. Image Credit: strannik65 / Shutterstock

Novel intranasal therapeutic option to target SARS-CoV-2 RNA using antisense oligonucleotides

Researchers from the US and Denmark recently described a novel therapeutic option that targets the SARS-CoV-2 ribonucleic acid (RNA) using locked nucleic acid antisense oligonucleotides (LNA ASOs). They identified an LNA ASO that binds to the 5’ leader sequence of SARS-CoV-2 ORF1a/b. This disrupts a highly conserved stem-loop structure with nanomolar efficacy and inhibits viral replication in host cells. The team’s study has been released as a preprint on the bioRxiv* server.

Antisense therapy is currently used in clinical treatment for a range of different diseases, including cytomegalovirus retinitis (Fomivirsen), Duchenne muscular dystrophy (Eteplirsen), and Spinal Muscular Atrophy (Nusinersen).”

LNA ASOs inhibit SARS-CoV-2 replication and infection in mice and hamsters

The LNA ASO, when administered intranasally every day in the K18-hACE2 humanized COVID-19 mouse model, strongly (98-99%) suppressed viral replication in the lungs of the SARS-CoV-2-infected mice. This reveals potent prophylactic as well as treatment effects of LNA ASOs. The researchers found that the LNA ASO also inhibits viral infection in golden Syrian hamsters and is effective against all SARS-CoV-2 “variants of concern,” including B.1.427, B.1.1.7, and B.1.351, with high efficacy in both in vitro and in vivo studies.

LNA ASOs can override the challenge of viral mutations thanks to their ability to design sequences that are specifically targeted to highly conserved and key regulatory regions of the viral genome. In addition, LNA ASO cocktails that target multiple critical regions of the viral genome may further improve the efficacy of LNA ASOs as therapeutic candidates to overcome viral mutations.

Use of LNA ASOs may be a promising treatment approach to reduce the transmission of vaccine-resistant SARS-CoV-2 variants

The continuous evolution of SARS-CoV-2 and the emergence of new, more dangerous variants with increased morbidity and mortality poses a huge challenge to reaching “herd immunity.” Traditional methods of drug screening and vaccine development are time-consuming and may not be able to match the speed with which drug- or vaccine-resistant SARS-CoV-2 variants are emerging. Hence there is a compelling need for alternative approaches to the rapid development of drugs that effectively act against all variants of concern.

Based on the findings of the study, the authors conclude that LNA ASOs that target SARS-CoV-2 can be a promising therapeutic approach to reduce the transmission of new SARS-CoV-2 variants that are partially resistant to monoclonal antibodies and vaccines. These LNA ASOs could be administered intranasally for prophylaxis or by lung delivery using a nebulizer to decrease symptoms in severe COVID-19 patients.

LNA ASOs are chemically stable compounds that can be stored for use during future pandemics

Given the relatively small size of RNA viral genomes and the ability to rapidly sequence any genome using next-generation sequencing techniques, anti-viral LNA ASOs can be designed and screened in a fast and efficient manner that allows rapid response to all kinds of health crises.

LNA ASOs are chemically stable compounds and can be modified to target various viral RNA sequences. They can be more impactful in remote areas where vaccine distribution is challenging, and they could also be stockpiled for use during other pandemics caused by coronaviruses that may threaten humanity in the future.

In conclusion, we have identified an intranasally delivered LNA ASO targeting the 5’ leader sequence as a viable therapeutic approach for preventing or treating SARS-CoV-2 infections, including those caused by variants of concern, indicating that LNA ASOs can be pursued as lead candidates for the treatment of COVID-19.”

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Susha Cheriyedath

Written by

Susha Cheriyedath

Susha has a Bachelor of Science (B.Sc.) degree in Chemistry and Master of Science (M.Sc) degree in Biochemistry from the University of Calicut, India. She always had a keen interest in medical and health science. As part of her masters degree, she specialized in Biochemistry, with an emphasis on Microbiology, Physiology, Biotechnology, and Nutrition. In her spare time, she loves to cook up a storm in the kitchen with her super-messy baking experiments.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cheriyedath, Susha. (2021, May 20). Intranasal COVID-19 therapeutic shows promise in preclinical trials. News-Medical. Retrieved on May 23, 2022 from

  • MLA

    Cheriyedath, Susha. "Intranasal COVID-19 therapeutic shows promise in preclinical trials". News-Medical. 23 May 2022. <>.

  • Chicago

    Cheriyedath, Susha. "Intranasal COVID-19 therapeutic shows promise in preclinical trials". News-Medical. (accessed May 23, 2022).

  • Harvard

    Cheriyedath, Susha. 2021. Intranasal COVID-19 therapeutic shows promise in preclinical trials. News-Medical, viewed 23 May 2022,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Ensitrelvir demonstrates swift SARS-CoV-2 clearance and safety among individuals with asymptomatic, mild, or moderate SARS-CoV-2 infections